The impact of mutational status on patient-reported outcomes in advanced non-small-cell lung cancer: a cross sectional study in France and Germany.

Objectives: Health-related quality of life (HRQoL) studies in patients with advanced non-small-cell lung cancer (NSCLC) according to mutational status are limited. This study aimed to report real-world evidence on HRQoL outcomes based on mutational status in patients with advanced NSCLC tumors receiving second-line or later (2L+) treatment in France and Germany.

Methods: In this real-world, non-interventional, cross-sectional, multicenter, patient-reported outcome (PRO) study conducted in France (15 contributing sites) and Germany (8 contributing sites), physicians enrolled adult patients with locally advanced and unresectable or metastatic NSCLC with known mutation status ( G12C, non-G12C, or wildtype [WT]), who received a 2L + treatment.

[Not Available].

The shift from electronic identification to digital identity is indicative of a shift in the spirit of the European texts. Whereas the legislator had thought of a purely technical identification process in 2014, in 2021 it is focusing on the role of the individual. The individual must be at the heart of the decision-making process as soon as data relating to his or her identity are concerned.

Immune checkpoint inhibitors in sarcomas: a systematic review.

Sarcomas are tumors that originate from mesenchymal cells. The variety of sarcomas' response to chemotherapy and the wide range of prognosis reflect their heterogeneity. In order to improve the rates of response, the research has been orientated toward other forms of therapy, such as targeted therapies and immunotherapy or toward combinations of them.

Amplifications and Metabolic Rewiring in Neuroblastoma.

Cancer is a disease caused by (epi)genomic and gene expression abnormalities and characterized by metabolic phenotypes that are substantially different from the normal phenotypes of the tissues of origin. Metabolic reprogramming is one of the key features of tumors, including those established in the human nervous system. In this work, we emphasize a well-known cancerous genomic alteration: the amplification of and its downstream effects in neuroblastoma phenotype evolution.

Symptoms and Experiences with Small Cell Lung Cancer: A Mixed Methods Study of Patients and Caregivers.

Introduction: Understanding of the patient-perceived symptom burden of small cell lung cancer (SCLC) is limited. The objective of this study was to explore patients' experiences with SCLC, identify which treatment-/disease-related symptoms have the greatest impact on their well-being, and gain caregiver perspectives.

Methods: A noninterventional, cross-sectional, multimodal, mixed methods study was conducted from April-June 2021.